Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs

Open access


A pharmacokinetic comparison and conformational stability study of S-oxiracetam (S-ORT) and R-oxiracetam (R-ORT) in beagle dogs was used to investigate the possible mechanism of different effects of two oxiracetam enantiomers through a random crossover design. After drug administration to beagle dogs, blood samples were collected at different time points for pharmacokinetic analysis using the UPLC-ESI-MS/MS method. Parts of plasma samples were used for conformation transformation studies using a normal phase high performance liquid chromatographic (NP HPLC) method. The study showed that oxiracetam enantiomers maintained their original conformation when administered orally to beagle dogs. Concentrations of S-ORT were significantly higher than R-ORT 1.5 and 2 h after administration; the AUC0-∞ of S-ORT after oral administration tended to be higher than that of R-ORT, which showed that the different effects between S-ORT and R-ORT may be partly associated with their distinctive absorption at least.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Z. Hlinak J. Vinsova and E. Kasafirek Effect of alaptide its analogues and oxiracetam on memory for an elevated plus-maze in mice Eur. J. Pharmacol. 314 (1996) 1–7.

  • 2. Z. Hlinak and I. Krejci Oxiracetam pre-but not post-treatment prevented social recognition deficits produced with trimethyltin in rats Behav. Brain Res. 161 (2005) 213–219; DOI: 10.1016/j.bbr.2005.02.030.

  • 3. C. Mondadori B. Hengerer T. Ducret and J. Borkowski Delayed emergence of effects of memoryenhancing drugs: implications for the dynamics of long-term memory Proc. Natl. Acad. Sci. USA 91 (1994) 2041–2045.

  • 4. C. Mondadori H. J. Möbius and J. Borkowski The GABAB receptor antagonist CGP 36742 and the nootropic oxiracetam facilitate the formation of long-term memory Behav. Brain Res. 77 (1996) 223–225.

  • 5. W. H. Brooks W. C. Guida and K. G. Daniel The significance of chirality in drug design and development Curr. Top. Med. Chem. 11 (2011) 760–770; DOI: 10.2174/156802611795165098.

  • 6. A. J. Hutt Chirality and pharmacokinetics: an area of neglected dimensionality Drug Metabol. Drug Interact. 22 (2007) 79–112; DOI: 10.1515/DMDI.2007.22.2-3.79.

  • 7. T. Kolev M. Spiteller and B. Koleva Spectroscopic and structural elucidation of amino acid derivatives and small peptides: experimental and theoretical tools Amino Acids 38 (2010) 45–50; DOI: 10.1007/s00726-008-0220-9.

  • 8. H. Lu Stereoselectivity in drug metabolism Expert Opin. Drug Metab. Toxicol. 3 (2007) 149–158; DOI: 10.1517/17425255.3.2.149.

  • 9. Q. Shen L. Wang H. Zhou L. S. Yu and S. Zeng Stereoselective binding of chiral drugs to plasma proteins Acta Pharmacol. Sinica 34 (2013) 998–1006; DOI: 10.1038/aps.2013.78.

  • 10. N. Inotsume and M. Nakano Stereoselective determination and pharmaco-kinetics of dihydropyridines: an updated review J. Biochem. Biophys. Methods 54 (2002) 255–274; DOI: 10.1016/S0165-022X(02)00120-3.

  • 11. R. Mehvar and D. R. Brocks Stereospecific pharmacokinetics and pharmacodynamics of betaadrenergic blockers in humans J. Pharm. Pharm. Sci. 4 (2001) 185–200.

  • 12. L.A. Nguyen H. He and C. Pham-Huy Chiral drugs: an overview Int. J. Biomed. Sci. 2 (2006) 85–100.

  • 13. L. Chiodini G. Pepeu Composition Comprising S-oxiracetame for Use as Nootropic EP. WO 1993006826 A1 15 April 1993; ref. Chem. Abstr. 119 (1993) 139083.

  • 14. W. S. Wang H. Ji H. T. Xie M. Dai Y. W. Jia D. H. Liang L. Ye and Z. Y. Rong A sensitive and specific UPLC–MS/MS analysis and preliminary pharmacokinetic characterization of S-oxiracetam in beagle dogs Chin. J. Clin. Pharmacol Ther. 17 (2012) 988–994.

  • 15. J. B. Lecaillon J. P. Dubois H. Coppens T. Darragon W. Theobald G. Reumond and H. Beck Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses comparison with nongeriatric healthy subjects Eur. J. Drug Metab. Pharmacokinet. 15 (1990) 223–237.

  • 16. E. Perucca A. Albrici G. Gatti R. Spalluto M. Visconti and A. Crema Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers Eur. J. Drug Metab. Pharmacokinet. 9 (1984) 267–274.

  • 17. E. Perucca J. Parini A. Albrici M. Visconti and E. Ferrero Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly Eur. J. Drug Metab. Pharmacokinet. 12 (1987) 145148.

  • 18. X. Wan H. Wang P. Ma L. Xi J. Sun Z. He X. Zhang and X. Liu Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC–MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration J. Chromatogr. B. 969 (2014) 95–100; DOI: 10.1016/j.jchromb.2014.07.041.

Journal information
Impact Factor

IMPACT FACTOR 2018: 1.405
5-year IMPACT FACTOR: 1.701

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.314
Source Normalized Impact per Paper (SNIP) 2018: 0.637

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 331 175 27
PDF Downloads 171 100 8